Research & development

Development Code / Nonproprietary Name	Classification	Indications

Pitavastatin	HMG-CoA reductase inhibitor	Dyslipidemia
Pitavastatin/Ezetimibe	HMG-CoA reductase inhibitor/NPC1L1 inhibitor	Dyslipidemia
Ripasudil	Rho kinase inhibitor	Glaucoma and ocular hypertension Fuchs endothelial corneal dystrophy
Ripasudil/Brimonidine	Rho kinase inhibitor/Alpha-2 adrenergic receptor agonist	Glaucoma and ocular hypertension
Pemafibrate	Selective PPARα modulator	Dyslipidemia Primary biliary cholangitis
Pemafibrate/ Tofogliflozin	Selective PPARα modulator/ SGLT2 inhibitor	Non-alcoholic steatohepatitis

Key products undergoing investigation in Europe as part of a global research program are:

Ripasudil

Notes

Only a product in Clinical Stage is listed. This list does not include all of the products.
A product in Clinical Stage is defined as a product for which a regulatory procedure has been made for initiation of a first clinical trial (i.e. Investigational New Drug application in US, Clinical Trial Application in Europe, Clinical Trial Notification in Japan, or a similar process in other regions) and a regulatory procedure for discontinuation of development has not been made or regulatory approval has not been obtained in any regions where approval is anticipated.
A product assigned with International Nonproprietary Name (INN) is listed as its nonproprietary name. Otherwise, a development code is used.
This list shows the most advanced development phase for a product which is in more than one phase amongst countries and/or regions. In addition, countries and regions where regulatory application for marketing authorization (e.g. New Drug Application in US) has been filed with an approval yet to be granted, are also listed.
This list also includes a product in Clinical Stage for new indication(s) even if it has been already approved for different indication(s).

For more information on our research and development program visit https://www.kowa.co.jp/eng/business/health/development.html